TJ Biopharma and Jumpcan Secure BE Trial Approval for Localized Eftansomatropin in China
TJ Biopharma (Hangzhou) Co., Ltd. and Jumpcan Holdings Group announced that the Center for Drug...
Jumpcan Pharmaceutical
Jumpcan Pharmaceutical’s Jike Shu Approved by NMPA for Influenza A and B Treatment
Shanghai-based Jumpcan Pharmaceutical (SHA: 600566) announced that its independently developed Class 1 innovative drug, Jike...
Eisai Transfers Pariet Rights in China to CBC Group-Controlled Peak Pharma
Japan-based Eisai (TYO: 4523) announced a strategic decision to transfer the rights of its proton...
TJ Biopharma and Jumpcan Pharmaceutical Announce NMPA Review of Eftansomatropin Alfa BLA
Chinese partners TJ Biopharma and Jumpcan Pharmaceutical (SHA: 600566) have jointly announced that the National...
Jumpcan Pharmaceutical Partners with Nanjing Zenshine for Exclusive Promotion Rights of ZX-7101A in China
China-based Jumpcan Pharmaceutical (SHA: 600566) has announced a strategic partnership with fellow Chinese firm Nanjing...
Jumpcan Partners with Newsoara for PDE4 and Protease Inhibitors in China
China-based Jumpcan Pharmaceutical (SHA: 600566) has announced a partnership with compatriot firm Newsoara BioPharma Co.,...
China Pharma H1 2022 Financials: 40% of Firms Report Revenue and Profit Growth
A total of 449 pharmaceutical and health-tech companies listed in China have released their H1...